This story has been updated to note that Amgen has declined its option to negotiate an agreement to develop, manufacture and commercialize SARS-CoV-2 neutralizing antibodies found by Adaptive Biotechnologies.
NEW YORK – Adaptive Biotechnologies is gearing up to launch a clinical test for T-cell response to COVID-19.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.